Literature DB >> 16467692

Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy.

Michael Colucciello1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16467692     DOI： 10.1097/00006982-200602000-00027

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  42 in total

1.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  Shiu Ting Mak; Albert Chak-ming Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-10       Impact factor: 3.117

2.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

3.  A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).

Authors:  Mitzy E Torres-Soriano; Gerardo García-Aguirre; Verónica Kon-Jara; Orlando Ustariz-Gonzáles; Maura Abraham-Marín; Michael D Ober; Hugo Quiroz-Mercado
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-04       Impact factor: 3.117

4.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

5.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

6.  Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.

Authors:  S H Karakus; B Basarir; E Y Pinarci; E U Kirandi; A Demirok
Journal:  Eye (Lond)       Date:  2013-03-22       Impact factor: 3.775

Review 7.  Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.

Authors:  H Q Lu; E Q Wang; T Zhang; Y X Chen
Journal:  Eye (Lond)       Date:  2015-10-30       Impact factor: 3.775

8.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

9.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

10.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.